服務(wù)熱線
400-021-2200
| 品牌 | StemRD/美國 |
|---|
產(chǎn)品信息
Hedgehog（Hh） 信號通路調(diào)節(jié)胚胎發(fā)育和成體許多組織器官干細(xì)胞的自我更新與增殖。然而，那些在正常發(fā)育過程中受到Hh信號通路調(diào)節(jié)的組織器官，在該信號通路異常時常常發(fā) 生腫瘤。這些腫瘤包括肝癌、神經(jīng)膠質(zhì)瘤、基底細(xì)胞癌、橫紋肌肉瘤、胰腺癌、小細(xì)胞肺癌、胃癌、結(jié)腸癌、前列腺癌、黑色素瘤和多發(fā)性骨髓瘤等。
LDE225 (NVP-LDE225):
A potent antagonist of SMO (smoothened). This small molecule compound is a hedgehog pathway inhibitor by directly binding to SMO. This molecule has been developed by the Novartis Pharma for clinical application against hedgehog-dependent cancers.
Purity:
Greater than 99% as determined by LC/MS analysis. LC/MS and/or NMR data available upon request.
Biological Activity:
In a cell-based assay measuring the activation of the Gli-1 reporter gene, this compound gives IC50 of 15-40 nM.
重慶市華雅干細(xì)胞技術(shù)有限公司